April 23, 2018Clinical Cancer Research312 citationsOpen Access
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Key Points
- Determine whether baseline tumor size acts as an independent prognostic factor for overall survival in patients with melanoma receiving pembrolizumab.
- Assessed melanoma patients undergoing immunotherapy with pembrolizumab.
- Measured pretreatment baseline tumor dimensions and correlated tumor burden with clinical survival outcomes.
- Baseline tumor size was established as an independent prognostic factor for overall survival.
- Patients with smaller baseline tumor burden exhibited significantly improved overall survival compared to those with larger baseline tumors.
Abstract
.